← Eichor
Condition: Locally Advanced Thyroid Gland Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Locally Advanced Thyroid Gland Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Phase 2 · 2 location(s) · Jochen Lorch · NCT06959641RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer
Phase N/A · 1 location(s) · Fudan University · NCT06524167Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359847A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
Phase N/A · 1 location(s) · Fujian Medical University · NCT07419932Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Phase 2 · 1 location(s) · West China Hospital · NCT06482086A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carc
Phase 3 · 35 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06860971Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
NA · 1 location(s) · Nanjing First Hospital, Nanjing Medical University · NCT06405217Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05989425Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Adv
NA · 1 location(s) · Nanjing First Hospital, Nanjing Medical University · NCT06431620Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
Phase 2 · 1 location(s) · Yu Wang · NCT06787911Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Diff
Phase N/A · 3 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT05994365MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC
Phase 2 · 1 location(s) · Fudan University · NCT07235566Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06970353Adjuvant Radiotherapy in High Risk Locally Advanced DTC
Phase 3 · 1 location(s) · Fudan University · NCT06558981RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer
Phase N/A · 1 location(s) · Fudan University · NCT06530316
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.